← 產業報告目錄

Assisted Reproductive Technology Market by Technology (In Vitro Fertilization, Artificial Insemination), Type (Instruments (Incubators), Media (Cryopreservation), Supplements, Consumables), Patient Type (Male, Female), End User - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-03-26頁數 321報告編號 MD9335

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The assisted reproductive technology market is projected to reach USD 6.02 Billion by 2030 from USD 4.29 Billion in 2025 at a CAGR of 7.0% during the forecast period. Increasing rates of infertility due to delayed conception, altered lifestyles, and growing awareness of fertility treatment are driving the assisted reproductive technology (ART) market. Further impetus to market growth is coming from improvements in medical technology, improved treatment success rates with in-vitro fertilization (IVF), and favorable government policies. But some of these limitations are the cost of treatment, ethical and legal issues, and health risks associated with ART procedures. Inadequacy of fertility treatment in developing nations and physical and psychological stress of ART also limit market growth. Research and development are, in spite of these limitations, enhancing the price and effectiveness of ART treatments. “The IVF segment is accounted for the largest share of global assisted reproductive technology market.” IVF has become the ART procedure of choice over other treatments due to innovations like time-lapse imaging, embryo freezing, and preimplantation genetic testing (PGT), which have greatly enhanced IVF success. Global demand for IVF has also been driven by delayed pregnancy, rising infertility, and greater awareness of fertility treatment. IVF domination of the market is also driven by greater medical tourism practice, government subsidization of ART procedures, and greater numbers of fertility clinics. Due to its high success rates, commonality of use, and ongoing technological advancements, the IVF category maintains the largest market share in the assisted reproductive technology (ART) market. The best treatment for infertility, in vitro fertilization (IVF), can treat many different kinds of infertility problems, including unexplained infertility, male factor infertility, and older mother age. “Fertility clinics has the largest market share in assisted reproductive technology market.” Fertility clinics enjoy the largest market share among the assisted reproductive technology market in care facilities owing to the growing demand for specialist reproductive treatments, high-technology healthcare facilities, and the increased number of infertile patients worldwide. Since ART therapies provided are heterogeneous in nature, encompassing intrauterine insemination, in-vitro fertilization, freezing eggs and sperm, and preimplantation genetic diagnosis, fertility clinics remain the preferred option for those who require fertility therapies. Expansion of private fertility clinics, government initiatives, and growing awareness regarding reproductive therapies have also driven the growth of this segment. Fertility clinics' dominance in the ART business is also complemented by the growing trend of medical tourism for affordable ART therapy in Thailand, India, and Spain. “Asia Pacific holds the largest market share in the assisted reproductive technology market.” Asia-Pacific holds the maximum market share in the ART market due to its large population, large infertility rates, and strong awareness of fertility treatment. There is growing demand for ART treatment in the region at a rapid rate due to factors such as delayed parenthood, changing lifestyles, and high levels of stress that exacerbate fertility. Government-sponsored programs for ART funding, the proliferation of fertility clinics, and advances in reproductive technology have all contributed to the growth in the market. Key drivers are countries such as China, India, and Japan, which offer low-cost fertility treatments that are in great demand among medical tourists. Asia-Pacific's market dominance is also supported by increasing acceptance of ART as well as the increase in the affordability of healthcare and infrastructure. A breakdown of the primary participants (supply-side) for the assisted reproductive technology market referred to for this report is provided below: • By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3–30% • By Designation: C-level–55%, Director Level–27%, and Others–18% • By Region: North America–35%, Europe–32%, Asia Pacific–25%, Latin America- 5%, and Middle East and Africa– 1% and GCC Countries– 2% Prominent players in this market include CooperSurgical Inc. (US), FUJIFILM Irvine Scientific (Japan), Vitrolife (Sweden), Hamilton Thorne (US), Cook Medical Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea BIOMEDX (Australia), Thermo Fisher Scientific Inc. (US), LENUS Pharma GesmbH (Austria), Zita West (UK), Kitazato Corporation (Japan), Exeltis USA, Inc. (US), Vitabiotics Ltd (UK), FertiPro NV (Belgium), and AdvaCare Pharma (US), among others. Research Coverage: The market study covers the assisted reproductive technology market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by type, technology, patient type, care setting and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies. Reasons to Buy the Report This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market. This report provides insights on:  Analysis of Market Dynamics: Drivers (Increasing median age of pregnancy, Rising infertility rate, Booming fertility industry, Evolving technological landscape, Favorable government initiatives) restraints (High cost of IVF procedures, Social and ethical concerns in developing countries, Elevated risk of complications) opportunities (Growth opportunities in emerging economies, Availability of diverse range of fertility treatment options), and challenges (Reduced efficacy of infertility treatments among patients of advanced age)  Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new product launches in the assisted reproductive technology market.  Market Development: Comprehensive information on the lucrative emerging markets, components, demographics, care settings, and region.  Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the assisted reproductive technology market.  Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the assisted reproductive technology market like CooperSurgical Inc. (US), FUJIFILM Irvine Scientific (Japan), Vitrolife (Sweden), Hamilton Thorne (US), Cook Medical Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea BIOMEDX (Australia), and Thermo Fisher Scientific Inc. (US).
目錄 Table of Contents
1 INTRODUCTION 29 1.1 STUDY OBJECTIVES 29 1.2 MARKET DEFINITION 30 1.3 STUDY SCOPE 30 1.3.1 MARKETS COVERED AND REGIONAL SCOPE 30 1.3.2 INCLUSIONS AND EXCLUSIONS 31 1.3.3 YEARS CONSIDERED 32 1.4 CURRENCY CONSIDERED 32 1.5 STAKEHOLDERS 33 2 RESEARCH METHODOLOGY 34 2.1 RESEARCH DATA 34 2.2 RESEARCH DESIGN 34 2.2.1 SECONDARY RESEARCH 35 2.2.1.1 Key data from secondary sources 36 2.2.2 PRIMARY RESEARCH 37 2.2.2.1 Primary sources 37 2.2.2.2 Key industry insights 38 2.2.2.3 Breakdown of primary interviews 38 2.3 MARKET SIZE ESTIMATION 39 2.3.1 SUPPLY-SIDE ANALYSIS 40 2.3.2 BOTTOM-UP APPROACH 42 2.3.2.1 Company revenue estimation approach 42 2.3.2.2 Customer-based market estimation 43 2.3.2.3 Demand-side market size estimation 43 2.3.2.4 Growth forecast approach 44 2.4 DATA TRIANGULATION 47 2.5 MARKET SHARE ASSESSMENT 48 2.6 RESEARCH ASSUMPTIONS 48 2.7 RESEARCH LIMITATIONS 48 2.8 RISK ASSESSMENT 49 3 EXECUTIVE SUMMARY 50 4 PREMIUM INSIGHTS 55 4.1 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET OVERVIEW 55 4.2 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE AND COUNTRY 56 4.3 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 57 4.4 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: REGIONAL MIX 58 4.5 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DEVELOPED VS. DEVELOPING MARKETS 59 5 MARKET OVERVIEW 60 5.1 INTRODUCTION 60 5.2 MARKET DYNAMICS 61 5.2.1 DRIVERS 62 5.2.1.1 Increasing median age of pregnancy 62 5.2.1.2 Rising infertility rate 63 5.2.1.3 Booming fertility industry 64 5.2.1.4 Evolving technological landscape 65 5.2.1.5 Favorable government initiatives 67 5.2.2 RESTRAINTS 68 5.2.2.1 High cost of IVF procedures 68 5.2.2.2 Social and ethical concerns in developing countries 68 5.2.2.3 Elevated risk of complications 69 5.2.3 OPPORTUNITIES 70 5.2.3.1 Growth opportunities in emerging economies 70 5.2.3.2 Availability of diverse range of fertility treatment options 70 5.2.4 CHALLENGES 70 5.2.4.1 Reduced efficacy of infertility treatments for patients of advanced age 70 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 71 5.4 PRICING ANALYSIS 72 5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS 72 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION 73 5.5 VALUE CHAIN ANALYSIS 73 5.5.1 RESEARCH & PRODUCT DEVELOPMENT 75 5.5.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING 75 5.5.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES 75 5.6 SUPPLY CHAIN ANALYSIS 75 5.6.1 PROMINENT COMPANIES 75 5.6.2 SMALL AND MEDIUM-SIZED ENTERPRISES 75 5.6.3 END USERS 75 5.7 ECOSYSTEM ANALYSIS 76 5.8 INVESTMENT AND FUNDING SCENARIO 77 5.9 TECHNOLOGY ANALYSIS 78 5.9.1 KEY TECHNOLOGIES 78 5.9.1.1 Time-lapse technology 78   5.9.2 COMPLEMENTARY TECHNOLOGIES 79 5.9.2.1 Preimplantation genetic testing 79 5.9.3 ADJACENT TECHNOLOGIES 79 5.9.3.1 Sperm cryopreservation 79 5.9.3.2 Oocyte cryopreservation 80 5.10 PATENT ANALYSIS 81 5.11 TRADE DATA ANALYSIS 83 5.11.1 IMPORT DATA 83 5.11.2 EXPORT DATA 84 5.12 KEY CONFERENCES AND EVENTS, 2025–2026 85 5.13 CASE STUDY ANALYSIS 86 5.13.1 CASE STUDY 1: ENHANCED IVF RATES USING EMBRYOTOXICITY, PLATELET LEUKOCYTE AGGREGATES, AND NATURAL KILLER DIAGNOSIS 86 5.13.2 CASE STUDY 2: IMPROVED EMBRYO SELECTION THROUGH AI-DRIVEN PLATFORM 86 5.13.3 CASE STUDY 3: ASSESSMENT OF EMBRYO VIABILITY USING AI-DRIVEN SYSTEMS 87 5.14 REGULATORY LANDSCAPE 87 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 5.14.2 REGULATORY FRAMEWORK 90 5.14.2.1 North America 91 5.14.2.1.1 US 91 5.14.2.1.2 Canada 91 5.14.2.2 Europe 92 5.14.2.3 Asia Pacific 92 5.14.2.3.1 India 92 5.14.2.3.2 Japan 92 5.15 PORTER’S FIVE FORCES ANALYSIS 93 5.15.1 THREAT OF NEW ENTRANTS 94 5.15.2 THREAT OF SUBSTITUTES 94 5.15.3 BARGAINING POWER OF BUYERS 94 5.15.4 BARGAINING POWER OF SUPPLIERS 94 5.15.5 INTENSITY OF COMPETITIVE RIVALRY 94 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 95 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 95 5.16.2 BUYING CRITERIA 96 5.17 UNMET NEEDS 97 5.18 REIMBURSEMENT SCENARIO 97 5.19 IMPACT OF AI/GEN AI ON ASSISTED REPRODUCTIVE TECHNOLOGY MARKET 98 5.19.1 INTRODUCTION 98 5.19.2 MARKET POTENTIAL OF AI IN ASSISTED REPRODUCTIVE TECHNOLOGY 98 5.19.3 AI USE CASES 99 5.19.4 KEY COMPANIES IMPLEMENTING AI 100 5.19.5 FUTURE OF GENERATIVE AI IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET 100 6 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE 101 6.1 INTRODUCTION 102 6.2 IN VITRO FERTILIZATION 102 6.2.1 IVF WITH ICSI 103 6.2.1.1 Higher success rates than conventional methods to stimulate growth 103 6.2.2 IVF WITHOUT ICSI 104 6.2.2.1 Preferred choice for less severe infertility issues to facilitate growth 104 6.3 ARTIFICIAL INSEMINATION 105 6.3.1 GROWING PREFERENCE FOR MINIMALLY INVASIVE TREATMENTS TO DRIVE MARKET 105 7 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE 107 7.1 INTRODUCTION 108 7.2 INSTRUMENTS 108 7.2.1 EMBRYO INCUBATORS 109 7.2.1.1 Need for undisturbed and protective environment throughout incubation to aid growth 109 7.2.2 SPERM ANALYZER SYSTEMS 111 7.2.2.1 Capability to identify fertility problems and determine appropriate interventions to fuel market 111 7.2.3 MICROMANIPULATORS 113 7.2.3.1 Increased adoption of micromanipulators in intracytoplasmic sperm injections and embryo biopsies to boost market 113 7.2.4 OTHER INSTRUMENTS 115 7.3 MEDIA 116 7.3.1 EMBRYO CULTURE MEDIA 118 7.3.1.1 Close resemblance to natural environment to amplify growth 118 7.3.2 CRYOPRESERVATION MEDIA 119 7.3.2.1 Ability to protect cells from damage to drive market 119 7.3.3 SEMEN PROCESSING MEDIA 120 7.3.3.1 Growing application in washing, capacitation, and sperm selection to boost market 120 7.3.4 OVUM PROCESSING MEDIA 121 7.3.4.1 Ability to mimic natural conditions of female reproductive tract to aid growth 121 7.4 SUPPLEMENTS 122 7.4.1 RISING DEMAND FOR FERTILITY-ENHANCING SUPPLEMENTS TO SUPPORT GROWTH 122 7.5 CONSUMABLES 123 7.5.1 CULTURE DISHES & PLATES 124 7.5.1.1 Growing advancements in embryo incubation to drive market 124 7.5.2 STORAGE CONTAINERS 125 7.5.2.1 Increasing use of cryopreservation techniques to expedite growth 125 7.5.3 CRYOVIALS & TUBES 127 7.5.3.1 Growing trend of egg and embryo freezing for delayed parenthood to boost market 127 7.5.4 OTHER CONSUMABLES 128 8 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE 129 8.1 INTRODUCTION 130 8.2 FEMALE PATIENTS 130 8.2.1 RISING FEMALE INFERTILITY RATE TO AMPLIFY GROWTH 130 8.3 MALE PATIENTS 131 8.3.1 LIFESTYLE CHANGES AND INCREASING INCIDENCE OF LOW SPERM COUNT TO PROMOTE GROWTH 131 9 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER 133 9.1 INTRODUCTION 134 9.2 FERTILITY CLINICS 134 9.2.1 INCREASED AVAILABILITY AND ACCESSIBILITY OF FERTILITY CLINICS TO SUSTAIN GROWTH 134 9.3 HOSPITALS & SURGERY CLINICS 135 9.3.1 NEED FOR ADVANCED LABORATORIES FOR GAMETE HANDLING AND ULTRASOUND MONITORING TO AID GROWTH 135 9.4 RESEARCH INSTITUTES 137 9.4.1 ONGOING RESEARCH FOR COST-EFFECTIVE AND ADVANCED TECHNIQUES TO STIMULATE GROWTH 137 9.5 CRYOBANKS 138 9.5.1 GROWING INCLINATION TOWARD FLEXIBLE TREATMENT TO FUEL MARKET 138 10 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION 140 10.1 INTRODUCTION 141 10.2 NORTH AMERICA 142 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 142 10.2.2 US 147 10.2.2.1 Favorable infrastructure network to encourage growth 147 10.2.3 CANADA 151 10.2.3.1 Growing assistance from banks for fertility treatments to fuel market 151 10.3 EUROPE 156 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 157 10.3.2 GERMANY 162 10.3.2.1 Robust healthcare infrastructure to support growth 162 10.3.3 UK 166 10.3.3.1 Increasing focus on high-quality care at licensed fertility clinics to propel market 166 10.3.4 FRANCE 170 10.3.4.1 Growing healthcare expenditure to boost market 170 10.3.5 ITALY 174 10.3.5.1 Favorable regulatory guidelines to support market growth 174 10.3.6 SPAIN 178 10.3.6.1 Booming medical tourism to drive market 178 10.3.7 REST OF EUROPE 182 10.4 ASIA PACIFIC 186 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 187 10.4.2 CHINA 193 10.4.2.1 Increasing medical benefits for childbirth to intensify growth 193 10.4.3 JAPAN 197 10.4.3.1 Low fertility rates to amplify growth 197 10.4.4 INDIA 201 10.4.4.1 Affordable treatment options to favor growth 201 10.4.5 AUSTRALIA 205 10.4.5.1 Declining fertility rate to advance growth 205 10.4.6 SOUTH KOREA 209 10.4.6.1 Growing focus on reversing low population trend to drive market 209 10.4.7 REST OF ASIA PACIFIC 213 10.5 LATIN AMERICA 217 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 217 10.5.2 BRAZIL 222 10.5.2.1 Rise in aging mothers to contribute to growth 222 10.5.3 MEXICO 226 10.5.3.1 Growing network of state-of-the-art facilities to boost market 226 10.5.4 REST OF LATIN AMERICA 230 10.6 MIDDLE EAST & AFRICA 234 10.6.1 RISING HEALTHCARE SPENDING TO FOSTER GROWTH 234 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 235 10.7 GCC COUNTRIES 239 10.7.1 IMPROVED HEALTH INFRASTRUCTURE AND BETTER AWARENESS ABOUT FERTILITY TREATMENTS TO PROPEL MARKET 239 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 240 11 COMPETITIVE LANDSCAPE 245 11.1 OVERVIEW 245 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 245 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET 246 11.3 REVENUE ANALYSIS, 2020–2024 247 11.4 MARKET SHARE ANALYSIS, 2024 248 11.5 COMPANY VALUATION AND FINANCIAL METRICS 250 11.5.1 COMPANY VALUATION 250 11.5.2 FINANCIAL METRICS 250 11.6 BRAND/PRODUCT COMPARISON 251 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 252 11.7.1 STARS 252 11.7.2 EMERGING LEADERS 252 11.7.3 PERVASIVE PLAYERS 252 11.7.4 PARTICIPANTS 252 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 254 11.7.5.1 Company footprint 254 11.7.5.2 Region footprint 255 11.7.5.3 Type footprint 256 11.7.5.4 Product type footprint 257 11.7.5.5 Patient type footprint 258 11.7.5.6 End-user footprint 259 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 260 11.8.1 PROGRESSIVE COMPANIES 260 11.8.2 RESPONSIVE COMPANIES 260 11.8.3 DYNAMIC COMPANIES 260 11.8.4 STARTING BLOCKS 260 11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 262 11.8.5.1 Detailed list of key startups/SMEs 262 11.8.5.2 Competitive benchmarking of key startups/SMEs 263 11.9 COMPETITIVE SCENARIO 263 11.9.1 PRODUCT LAUNCHES 263 11.9.2 DEALS 264 11.9.3 OTHER DEVELOPMENTS 265 12 COMPANY PROFILES 266 12.1 KEY PLAYERS 266 12.1.1 COOPERSURGICAL INC. 266 12.1.1.1 Business overview 266 12.1.1.2 Products offered 267 12.1.1.3 Recent developments 269 12.1.1.3.1 Deals 269 12.1.1.4 MnM view 269 12.1.1.4.1 Key strengths 269 12.1.1.4.2 Strategic choices 269 12.1.1.4.3 Weaknesses and competitive threats 269   12.1.2 FUJIFILM IRVINE SCIENTIFIC 270 12.1.2.1 Business overview 270 12.1.2.2 Products offered 271 12.1.2.3 Recent developments 271 12.1.2.3.1 Deals 271 12.1.2.3.2 Other developments 272 12.1.2.4 MnM view 272 12.1.2.4.1 Key strengths 272 12.1.2.4.2 Strategic choices 272 12.1.2.4.3 Weaknesses 272 12.1.3 VITROLIFE 273 12.1.3.1 Business overview 273 12.1.3.2 Products offered 275 12.1.3.3 Recent developments 275 12.1.3.3.1 Deals 275 12.1.3.4 MnM view 276 12.1.3.4.1 Key strengths 276 12.1.3.4.2 Strategic choices 276 12.1.3.4.3 Weaknesses and competitive threats 276 12.1.4 THERMO FISHER SCIENTIFIC INC. 277 12.1.4.1 Business overview 277 12.1.4.2 Products offered 278 12.1.4.3 MnM view 279 12.1.4.3.1 Key strengths 279 12.1.4.3.2 Strategic choices 279 12.1.4.3.3 Weaknesses and competitive threats 279 12.1.5 COOK MEDICAL INC. 280 12.1.5.1 Business overview 280 12.1.5.2 Products offered 280 12.1.5.3 Recent developments 281 12.1.5.3.1 Product launches 281 12.1.5.3.2 Deals 282 12.1.5.4 MnM view 282 12.1.5.4.1 Key strengths 282 12.1.5.4.2 Strategic choices 282 12.1.5.4.3 Weaknesses and competitive threats 282 12.1.6 HAMILTON THORNE 283 12.1.6.1 Business overview 283 12.1.6.2 Products offered 283 12.1.6.3 Recent developments 284 12.1.6.3.1 Deals 284 12.1.6.4 MnM view 285 12.1.6.4.1 Key strengths 285 12.1.6.4.2 Strategic choices 285 12.1.6.4.3 Weaknesses and competitive threats 285 12.1.7 KITAZATO CORPORATION 286 12.1.7.1 Business overview 286 12.1.7.2 Products offered 286 12.1.7.3 Recent developments 288 12.1.7.3.1 Deals 288 12.1.8 ESCO MICRO PTE. LTD. 289 12.1.8.1 Business overview 289 12.1.8.2 Products offered 289 12.1.8.3 Recent developments 290 12.1.8.3.1 Deals 290 12.1.9 FERTIPRO NV 291 12.1.9.1 Business overview 291 12.1.9.2 Products offered 291 12.1.10 GENEA BIOMEDX 293 12.1.10.1 Business overview 293 12.1.10.2 Products offered 293 12.1.10.3 Recent developments 294 12.1.10.3.1 Deals 294 12.1.11 LENUS PHARMA GESMBH 295 12.1.11.1 Business overview 295 12.1.11.2 Products offered 295 12.1.11.3 Recent developments 295 12.1.11.3.1 Product launches 295 12.1.12 ZITA WEST 296 12.1.12.1 Business overview 296 12.1.12.2 Products offered 296 12.1.13 EXELTIS USA, INC. 298 12.1.13.1 Business overview 298 12.1.13.2 Products offered 298 12.1.14 VITABIOTICS LTD. 299 12.1.14.1 Business overview 299 12.1.14.2 Products offered 299 12.1.15 ADVACARE PHARMA 301 12.1.15.1 Business overview 301 12.1.15.2 Products offered 301   12.2 OTHER COMPANIES 302 12.2.1 FAIRHAVEN HEALTH 302 12.2.2 SHANGHAI UNICORN MEDICAL TECHNOLOGY CO., LTD. 303 12.2.3 GYNEMED GMBH & CO. KG 304 12.2.4 INVITROCARE INC. 305 12.2.5 IVFTECH 306 12.2.6 LABIVF ASIA PTE LTD. 307 12.2.7 COAST SCIENCE 308 12.2.8 BIOIMAGER INC. 309 12.2.9 SHIVANI SCIENTIFIC 310 12.2.10 MINITÜB GMBH 311 13 APPENDIX 312 13.1 DISCUSSION GUIDE 312 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 317 13.3 CUSTOMIZATION OPTIONS 319 13.4 RELATED REPORTS 319 13.5 AUTHOR DETAILS 320
圖表清單 List of Tables & Figures
TABLE 1 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: INCLUSIONS AND EXCLUSIONS 31 TABLE 2 STANDARD CURRENCY CONVERSION RATES, 2019–2023 32 TABLE 3 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT TYPE, 2022–2024 (USD) 72 TABLE 4 AVERAGE SELLING PRICE TREND OF SUPPLEMENTS, BY REGION, 2022–2024 (USD) 73 TABLE 5 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 77 TABLE 6 INNOVATIONS AND PATENT REGISTRATIONS, 2022–2024 82 TABLE 7 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020–2024 (USD THOUSAND) 83 TABLE 8 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020–2024 (USD THOUSAND) 84 TABLE 9 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 85 TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89 TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89 TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90 TABLE 15 REGULATORY STANDARDS AND APPROVALS FOR ASSISTED REPRODUCTIVE TECHNOLOGY 90 TABLE 16 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 93 TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO END USERS (%) 95 TABLE 18 KEY BUYING CRITERIA FOR TOP TWO END USERS 96 TABLE 19 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: CURRENT UNMET NEEDS 97 TABLE 20 MAJOR CPT CODES FOR LASER PROCEDURES IN US, 2024 97 TABLE 21 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 102 TABLE 22 ASSISTED REPRODUCTIVE TYPE MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 102 TABLE 23 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY COUNTRY, 2022–2030 (USD MILLION) 103 TABLE 24 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF WITH ICSI, BY COUNTRY, 2022–2030 (USD MILLION) 104 TABLE 25 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF WITHOUT ICSI, BY COUNTRY, 2022–2030 (USD MILLION) 105 TABLE 26 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR ARTIFICIAL INSEMINATION, BY COUNTRY, 2022–2030 (USD MILLION) 106 TABLE 27 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 108 TABLE 28 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 108 TABLE 29 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 109 TABLE 30 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR EMBRYO INCUBATORS, BY COUNTRY, 2022–2030 (USD MILLION) 110 TABLE 31 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR EMBRYO INCUBATORS, BY REGION, 2022–2030 (THOUSAND UNITS) 111 TABLE 32 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR SPERM ANALYZER SYSTEMS, BY COUNTRY, 2022–2030 (USD MILLION) 112 TABLE 33 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR SPERM ANALYZER SYSTEMS, BY REGION, 2022–2030 (THOUSAND UNITS) 113 TABLE 34 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MICROMANIPULATORS, BY COUNTRY, 2022–2030 (USD MILLION) 114 TABLE 35 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MICROMANIPULATORS, BY REGION, 2022–2030 (THOUSAND UNITS) 115 TABLE 36 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 116 TABLE 37 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 117 TABLE 38 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY COUNTRY, 2022–2030 (USD MILLION) 117 TABLE 39 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR EMBRYO CULTURE MEDIA, BY COUNTRY, 2022–2030 (USD MILLION) 118 TABLE 40 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CRYOPRESERVATION MEDIA, BY COUNTRY, 2022–2030 (USD MILLION) 119 TABLE 41 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR SEMEN PROCESSING MEDIA, BY COUNTRY, 2022–2030 (USD MILLION) 120 TABLE 42 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR OVUM PROCESSING MEDIA, BY COUNTRY, 2022–2030 (USD MILLION) 121 TABLE 43 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR SUPPLEMENTS, BY COUNTRY, 2022–2030 (USD MILLION) 122 TABLE 44 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 123 TABLE 45 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2030 (USD MILLION) 124 TABLE 46 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CULTURE DISHES & PLATES, BY COUNTRY, 2022–2030 (USD MILLION) 125 TABLE 47 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR STORAGE CONTAINERS, BY COUNTRY, 2022–2030 (USD MILLION) 126 TABLE 48 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CRYOVIALS & TUBES, BY COUNTRY, 2022–2030 (USD MILLION) 127 TABLE 49 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR OTHER CONSUMABLES, BY COUNTRY, 2022–2030 (USD MILLION) 128 TABLE 50 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 130 TABLE 51 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR FEMALE PATIENTS, BY COUNTRY, 2022–2030 (USD MILLION) 131 TABLE 52 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MALE PATIENTS, BY COUNTRY, 2022–2030 (USD MILLION) 132 TABLE 53 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 134 TABLE 54 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2022–2030 (USD MILLION) 135 TABLE 55 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR HOSPITALS & SURGERY CLINICS, BY COUNTRY, 2022–2030 (USD MILLION) 136 TABLE 56 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION) 138 TABLE 57 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CRYOBANKS, BY COUNTRY, 2022–2030 (USD MILLION) 139 TABLE 58 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION, 2022–2030 (USD MILLION) 141 TABLE 59 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 144 TABLE 60 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 144 TABLE 61 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 144 TABLE 62 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 145 TABLE 63 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 145 TABLE 64 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 146 TABLE 65 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 146 TABLE 66 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 147 TABLE 67 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 147 TABLE 68 US: KEY MACROECONOMIC INDICATORS 148 TABLE 69 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 148 TABLE 70 US: IVF ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 148 TABLE 71 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 149 TABLE 72 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 149 TABLE 73 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 150 TABLE 74 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 150 TABLE 75 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 151 TABLE 76 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 151 TABLE 77 CANADA: KEY MACROECONOMIC INDICATORS 152 TABLE 78 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 153 TABLE 79 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 153 TABLE 80 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 154 TABLE 81 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 154 TABLE 82 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 155 TABLE 83 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 155 TABLE 84 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 156 TABLE 85 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 156 TABLE 86 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 158 TABLE 87 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 158 TABLE 88 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 159 TABLE 89 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 159 TABLE 90 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 160 TABLE 91 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 160 TABLE 92 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 161 TABLE 93 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 161 TABLE 94 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 162 TABLE 95 GERMANY: KEY MACROECONOMIC INDICATORS 162 TABLE 96 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 163 TABLE 97 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 163 TABLE 98 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 163 TABLE 99 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 164 TABLE 100 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 164 TABLE 101 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 165 TABLE 102 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 165 TABLE 103 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 166 TABLE 104 UK: KEY MACROECONOMIC INDICATORS 166 TABLE 105 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 167 TABLE 106 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 167 TABLE 107 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 168 TABLE 108 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 168 TABLE 109 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 169 TABLE 110 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 169 TABLE 111 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 170 TABLE 112 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 170 TABLE 113 FRANCE: KEY MACROECONOMIC INDICATORS 171 TABLE 114 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 171 TABLE 115 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 171 TABLE 116 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 172 TABLE 117 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 172 TABLE 118 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 173 TABLE 119 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 173 TABLE 120 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 174 TABLE 121 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 174 TABLE 122 ITALY: KEY MACROECONOMIC INDICATORS 175 TABLE 123 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 175 TABLE 124 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 175 TABLE 125 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 176 TABLE 126 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 176 TABLE 127 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 177 TABLE 128 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 177 TABLE 129 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 178 TABLE 130 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 178 TABLE 131 SPAIN: KEY MACROECONOMIC INDICATORS 179 TABLE 132 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 179 TABLE 133 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 179 TABLE 134 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 180 TABLE 135 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 180 TABLE 136 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 181 TABLE 137 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 181 TABLE 138 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 182 TABLE 139 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 182 TABLE 140 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 183 TABLE 141 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 183 TABLE 142 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 184 TABLE 143 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 184 TABLE 144 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 185 TABLE 145 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 185 TABLE 146 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 186 TABLE 147 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 186 TABLE 148 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 189 TABLE 149 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 189 TABLE 150 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 190 TABLE 151 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 190 TABLE 152 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 191 TABLE 153 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 191 TABLE 154 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 192 TABLE 155 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 192 TABLE 156 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 193 TABLE 157 CHINA: KEY MACROECONOMIC INDICATORS 194 TABLE 158 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 194 TABLE 159 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 194 TABLE 160 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 195 TABLE 161 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 195 TABLE 162 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 196 TABLE 163 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 196 TABLE 164 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 197 TABLE 165 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 197 TABLE 166 JAPAN: KEY MACROECONOMIC INDICATORS 198 TABLE 167 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 198 TABLE 168 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 198 TABLE 169 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 199 TABLE 170 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 199 TABLE 171 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 200 TABLE 172 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 200 TABLE 173 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 201 TABLE 174 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 201 TABLE 175 INDIA: KEY MACROECONOMIC INDICATORS 202 TABLE 176 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 202 TABLE 177 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 202 TABLE 178 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 203 TABLE 179 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 203 TABLE 180 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 204 TABLE 181 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 204 TABLE 182 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 205 TABLE 183 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 205 TABLE 184 AUSTRALIA: KEY MACROECONOMIC INDICATORS 206 TABLE 185 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 206 TABLE 186 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 206 TABLE 187 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 207 TABLE 188 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 207 TABLE 189 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 208 TABLE 190 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 208 TABLE 191 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 209 TABLE 192 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 209 TABLE 193 SOUTH KOREA: KEY MACROECONOMIC INDICATORS 210 TABLE 194 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 210 TABLE 195 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 210 TABLE 196 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 211 TABLE 197 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 211 TABLE 198 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 212 TABLE 199 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 212 TABLE 200 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 213 TABLE 201 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 213 TABLE 202 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 214 TABLE 203 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 214 TABLE 204 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 215 TABLE 205 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 215 TABLE 206 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 216 TABLE 207 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 216 TABLE 208 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 217 TABLE 209 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 217 TABLE 210 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 218 TABLE 211 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 218 TABLE 212 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 219 TABLE 213 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 219 TABLE 214 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 220 TABLE 215 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 220 TABLE 216 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 221 TABLE 217 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 221 TABLE 218 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 222 TABLE 219 BRAZIL: KEY MACROECONOMIC INDICATORS 222 TABLE 220 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 223 TABLE 221 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 223 TABLE 222 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 223 TABLE 223 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 224 TABLE 224 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 224 TABLE 225 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 225 TABLE 226 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 225 TABLE 227 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 226 TABLE 228 MEXICO: KEY MACROECONOMIC INDICATORS 227 TABLE 229 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 227 TABLE 230 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 227 TABLE 231 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 228 TABLE 232 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 228 TABLE 233 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 229 TABLE 234 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 229 TABLE 235 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 230 TABLE 236 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 230 TABLE 237 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 231 TABLE 238 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 231 TABLE 239 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 232 TABLE 240 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 232 TABLE 241 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 233 TABLE 242 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 233 TABLE 243 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 234 TABLE 244 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 234 TABLE 245 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 235 TABLE 246 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 236 TABLE 247 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 236 TABLE 248 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 237 TABLE 249 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 237 TABLE 250 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 238 TABLE 251 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 238 TABLE 252 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 239 TABLE 253 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 240 TABLE 254 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 241 TABLE 255 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 241 TABLE 256 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 242 TABLE 257 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 242 TABLE 258 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 243 TABLE 259 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 243 TABLE 260 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 244 TABLE 261 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, JANUARY 2021–MARCH 2025 246 TABLE 262 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DEGREE OF COMPETITION 248 TABLE 263 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: REGION FOOTPRINT 255 TABLE 264 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: TYPE FOOTPRINT 256 TABLE 265 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: PRODUCT TYPE FOOTPRINT 257 TABLE 266 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: PATIENT TYPE FOOTPRINT 258 TABLE 267 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: END-USER FOOTPRINT 259 TABLE 268 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 262 TABLE 269 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 263 TABLE 270 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2025 264 TABLE 271 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DEALS, JANUARY 2021–MARCH 2025 264 TABLE 272 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2025 265 TABLE 273 COOPERSURGICAL INC.: COMPANY OVERVIEW 266 TABLE 274 COOPERSURGICAL INC.: PRODUCTS OFFERED 267 TABLE 275 COOPERSURGICAL INC.: DEALS, JANUARY 2021–MARCH 2025 269 TABLE 276 FUJIFILM IRVINE SCIENTIFIC: COMPANY OVERVIEW 270 TABLE 277 FUJIFILM IRVINE SCIENTIFIC: PRODUCTS OFFERED 271 TABLE 278 FUJIFILM IRVINE SCIENTIFIC: DEALS, JANUARY 2021–MARCH 2025 271 TABLE 279 FUJIFILM IRVINE SCIENTIFIC: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2025 272 TABLE 280 VITROLIFE: COMPANY OVERVIEW 273 TABLE 281 VITROLIFE: PRODUCTS OFFERED 275 TABLE 282 VITROLIFE: DEALS, JANUARY 2021–MARCH 2025 275 TABLE 283 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 277 TABLE 284 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 278 TABLE 285 COOK MEDICAL INC.: COMPANY OVERVIEW 280 TABLE 286 COOK MEDICAL INC.: PRODUCTS OFFERED 280 TABLE 287 COOK MEDICAL INC.: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2025 281 TABLE 288 COOK MEDICAL INC.: DEALS, JANUARY 2021–MARCH 2025 282 TABLE 289 HAMILTON THORNE: COMPANY OVERVIEW 283 TABLE 290 HAMILTON THORNE: PRODUCTS OFFERED 283 TABLE 291 HAMILTON THORNE: DEALS, JANUARY 2021–MARCH 2025 284 TABLE 292 KITAZATO CORPORATION: COMPANY OVERVIEW 286 TABLE 293 KITAZATO CORPORATION: PRODUCTS OFFERED 286 TABLE 294 KITAZATO CORPORATION: DEALS, JANUARY 2021–MARCH 2025 288 TABLE 295 ESCO MICRO PTE. LTD.: COMPANY OVERVIEW 289 TABLE 296 ESCO MICRO PTE. LTD.: PRODUCTS OFFERED 289 TABLE 297 ESCO MICRO PTE. LTD.: DEALS, JANUARY 2021–MARCH 2025 290 TABLE 298 FERTIPRO NV: COMPANY OVERVIEW 291 TABLE 299 FERTIPRO NV: PRODUCTS OFFERED 291 TABLE 300 GENEA BIOMEDX: COMPANY OVERVIEW 293 TABLE 301 GENEA BIOMEDX: PRODUCTS OFFERED 293 TABLE 302 GENEA BIOMEDX: DEALS, JANUARY 2021–MARCH 2025 294 TABLE 303 LENUS PHARMA GESMBH: COMPANY OVERVIEW 295 TABLE 304 LENUS PHARMA GESMBH: PRODUCTS OFFERED 295 TABLE 305 LENUS PHARMA GESMBH: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2025 295 TABLE 306 ZITA WEST: COMPANY OVERVIEW 296 TABLE 307 ZITA WEST: PRODUCTS OFFERED 296 TABLE 308 EXELTIS USA, INC.: COMPANY OVERVIEW 298 TABLE 309 EXELTIS USA, INC.: PRODUCTS OFFERED 298 TABLE 310 VITABIOTICS LTD.: COMPANY OVERVIEW 299 TABLE 311 VITABIOTICS LTD.: PRODUCTS OFFERED 299 TABLE 312 ADVACARE PHARMA: COMPANY OVERVIEW 301 TABLE 313 ADVACARE PHARMA: PRODUCTS OFFERED 301 TABLE 314 FAIRHAVEN HEALTH: COMPANY OVERVIEW 302 TABLE 315 SHANGHAI UNICORN MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 303 TABLE 316 GYNEMED GMBH & CO. KG: COMPANY OVERVIEW 304 TABLE 317 INVITROCARE INC.: COMPANY OVERVIEW 305 TABLE 318 IVFTECH: COMPANY OVERVIEW 306 TABLE 319 LABIVF ASIA PTE LTD.: COMPANY OVERVIEW 307 TABLE 320 COAST SCIENCE: COMPANY OVERVIEW 308 TABLE 321 BIOIMAGER INC.: COMPANY OVERVIEW 309 TABLE 322 SHIVANI SCIENTIFIC: COMPANY OVERVIEW 310 TABLE 323 MINITÜB GMBH: COMPANY OVERVIEW 311 FIGURE 1 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SEGMENTATION AND REGIONAL SCOPE 30 FIGURE 2 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: RESEARCH DESIGN 34 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 38 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 39 FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 40 FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 41 FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: COOPERSURGICAL INC., 2024 41 FIGURE 8 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE ESTIMATION: COMPANY REVENUE ESTIMATION 42 FIGURE 9 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DEMAND-SIDE MARKET SIZE ESTIMATION 43 FIGURE 10 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DYNAMICS, 2025–2030 45 FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 46 FIGURE 12 DATA TRIANGULATION 47 FIGURE 13 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 50 FIGURE 14 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2025 VS. 2030 (USD MILLION) 51 FIGURE 15 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2025 VS. 2030 (USD MILLION) 52 FIGURE 16 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 53 FIGURE 17 GEOGRAPHICAL SNAPSHOT OF ASSISTED REPRODUCTIVE TECHNOLOGY MARKET 54 FIGURE 18 INCREASING INFERTILITY WORLDWIDE TO DRIVE MARKET 55 FIGURE 19 IVF SEGMENT AND CHINA DOMINATED ASIA PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET IN 2024 56 FIGURE 20 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 57 FIGURE 21 ASIA PACIFIC TO LEAD MARKET DURING FORECAST PERIOD 58 FIGURE 22 DEVELOPING MARKETS TO HAVE HIGHER CAGR DURING FORECAST PERIOD 59 FIGURE 23 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61 FIGURE 24 AVERAGE AGE OF FIRST-TIME MOTHERS IN US, 2001–2023 62 FIGURE 25 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET 71 FIGURE 26 AVERAGE SELLING PRICE TREND OF SUPPLEMENTS, BY REGION, 2022–2024 (USD) 73 FIGURE 27 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: VALUE CHAIN ANALYSIS 74 FIGURE 28 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: SUPPLY CHAIN ANALYSIS 76 FIGURE 29 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: ECOSYSTEM ANALYSIS 76 FIGURE 30 INVESTMENT AND FUNDING SCENARIO, 2019–2023 77 FIGURE 31 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 78 FIGURE 32 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 (USD MILLION) 78 FIGURE 33 PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024 81 FIGURE 34 PORTER’S FIVE FORCES ANALYSIS 93 FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO END USERS 95 FIGURE 36 KEY BUYING CRITERIA FOR TOP TWO END USERS 96 FIGURE 37 AI USE CASES 99 FIGURE 38 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SNAPSHOT 143 FIGURE 39 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SNAPSHOT 188 FIGURE 40 REVENUE ANALYSIS OF TOP PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, 2020–2024 (USD MILLION) 247 FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, 2024 248 FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025 250 FIGURE 43 EV/EBITDA OF KEY VENDORS, 2025 250 FIGURE 44 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: BRAND/PRODUCT COMPARISON 251 FIGURE 45 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 253 FIGURE 46 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: COMPANY FOOTPRINT 254 FIGURE 47 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 261 FIGURE 48 COOPERSURGICAL INC.: COMPANY SNAPSHOT (2024) 267 FIGURE 49 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT (2024) 270 FIGURE 50 VITROLIFE: COMPANY SNAPSHOT (2024) 274 FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 278

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們